Embryo implantation
AssigneeOstara Biomedical Ltd.
InventorsNadia Gopichandran, Nicolas Michel Orsi, David Andrew Brooke
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of and compositions comprising cytokines for, improving the success rate of embryo implantation and the success rate of pregnancy rates in females, by providing an immunopermissive uterine environment prior to insemination or implantation of embryos. The methods of the present invention are used to make the uterus more receptive or less hostile to, for example, transferred embryos, sperm or other allografted tissue.
Claims15
A composition of matter for use in improving pregnancy rates in females prior to implantation of an embryo or prior to insemination, the composition consisting essentially of recombinant IL-12 and recombinant GM-CSF, wherein the composition is configured to release the recombinant IL-12 and recombinant GM-CSF in situ in a vagina within a physiological concentration range as corresponding IL-12 and GM-CSF found in seminal fluid of a fertile male.
A pharmaceutical composition for use in improving pregnancy rates in females prior to implantation of an embryo or prior to insemination, the pharmaceutical composition consisting essentially of recombinant IL-12 and recombinant GM-CSF, and wherein the pharmaceutical composition is a vaginal insert, and wherein the pharmaceutical composition is configured to release the recombinant IL-12 and recombinant GM-CSF in situ in a vagina within a physiological concentration range as corresponding IL-12 and GM-CSF found in seminal fluid of a fertile male.
A composition of matter for use in improving pregnancy rates in females prior to implantation of an embryo or prior to insemination, the composition consisting essentially of any one, two, or three of recombinant TGFβ, recombinant Eotaxin and recombinant RANTES, wherein the composition-releases the any one, two, or three of the recombinant TGFβrecombinant Eotaxin and recombinant RANTES in situ in a vagina within a physiological concentration range as corresponding TGFβ, Eotaxin and RANTES found in seminal fluid of a fertile male.
A pharmaceutical composition of matter for use in improving pregnancy rates in females prior to implantation of an embryo or prior to insemination, the pharmaceutical composition consisting essentially of any one, two, or three of recombinant TGFβ, recombinant Eotaxin and recombinant RANTES, wherein the pharmaceutical composition is configured to release the any one, two, or three of the recombinant TGFβ, recombinant Eotaxin and recombinant RANTES in situ in a vagina within a physiological concentration range as corresponding TGFβ, Eotaxin and RANTES found in seminal fluid of a fertile male.
Dependencies are inferred from the claim text.